Walleye Trading’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-39,800
| Closed | -$1.6M | – | 3958 |
|
|
2026
Q1 | $1.6M | Buy |
39,800
+5,300
| +15% | +$114K | ﹤0.01% | 1838 |
|
|
2025
Q4 | $867K | Sell |
34,500
-2,100
| -6% | -$49.3K | ﹤0.01% | 2468 |
|
|
2025
Q3 | $828K | Buy |
36,600
+300
| +0.8% | +$7K | ﹤0.01% | 2396 |
|
|
2025
Q2 | $628K | Buy |
36,300
+4,700
| +15% | +$87K | ﹤0.01% | 2495 |
|
|
2025
Q1 | $691K | Sell |
31,600
-36,900
| -54% | -$1.02M | ﹤0.01% | 2307 |
|
|
2024
Q4 | $2.19M | Buy |
68,500
+45,200
| +194% | +$1.36M | ﹤0.01% | 1638 |
|
|
2024
Q3 | $672K | Buy |
23,300
+8,500
| +57% | +$315K | ﹤0.01% | 2334 |
|
|
2024
Q2 | $568K | Sell |
14,800
-10,600
| -42% | -$480K | ﹤0.01% | 2422 |
|
|
2024
Q1 | $1.49M | Sell |
25,400
-1,100
| -4% | -$70.1K | ﹤0.01% | 1924 |
|
|
2023
Q4 | $1.59M | Buy |
26,500
+13,400
| +102% | +$680K | ﹤0.01% | 2110 |
|
|
2023
Q3 | $498K | Buy |
13,100
+1,000
| +8% | +$43.9K | ﹤0.01% | 2965 |
|
|
2023
Q2 | $1.1M | Buy |
12,100
+3,300
| +38% | +$285K | ﹤0.01% | 2095 |
|
|
2023
Q1 | $580K | Sell |
8,800
-8,500
| -49% | -$490K | ﹤0.01% | 2666 |
|
|
2022
Q4 | $895K | Buy |
17,300
+3,600
| +26% | +$191K | ﹤0.01% | 2312 |
|
|
2022
Q3 | $936K | Sell |
13,700
-5,900
| -30% | -$349K | ﹤0.01% | 2297 |
|
|
2022
Q2 | $886K | Sell |
19,600
-400
| -2% | -$18.2K | ﹤0.01% | 2350 |
|
|
2022
Q1 | $1.02M | Buy |
+20,000
| New | +$883K | ﹤0.01% | 2217 |
|
|
2021
Q4 | – | Sell |
-48,600
| Closed | -$1.6M | – | 5308 |
|
|
2021
Q3 | $1.6M | Buy |
48,600
+43,000
| +768% | +$2.42M | 0.01% | 1798 |
|
|
2021
Q2 | $354K | Buy |
+5,600
| New | +$289K | ﹤0.01% | 3321 |
|
|
2020
Q3 | – | Sell |
-5,700
| Closed | -$186K | – | 4063 |
|
|
2020
Q2 | $186K | Sell |
5,700
-4,700
| -45% | -$151K | ﹤0.01% | 3116 |
|
|
2020
Q1 | $279K | Buy |
10,400
+7,700
| +285% | +$273K | ﹤0.01% | 2354 |
|
|
2019
Q4 | $83K | Buy |
+2,700
| New | +$74.7K | ﹤0.01% | 3637 |
|
Other funds holding APLS
Walleye Trading's APLS Position: Q2 2026 in Review
Walleye Trading sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 6,602 shares — an estimated $266K sold.
Walleye Trading first reported a position in APLS in Q1 2020 and held it in 12 quarters. The position peaked at $969K in Q3 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Walleye Trading reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Walleye Trading sold 6,602 Apellis Pharmaceuticals shares in Q2 2026, an estimated $266K.
- Walleye Trading first reported a position in Apellis Pharmaceuticals in Q1 2020 and held it in 12 quarters.
- Walleye Trading's Apellis Pharmaceuticals position peaked at $969K in Q3 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Walleye Trading's 13F filing for Q2 2026, filed 3 Aug 2026.